参考文献

1. Maher TM et al. Nerandomilast in Patients with Progressive Pulmonary Fibrosis. N Engl J Med 2025.

2. Maher TM. Interstitial Lung Disease: A Review. JAMA. 2024 May 21;331(19):1655-1665.1.

3. Keith R, et al. Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666241309795.

4. Huang H, Wang Q, Xu Z. Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts. Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241288417.

5. Lamb YN. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs. 2021 Apr;81(5):575-586. 

6. Cottin V, et al. Evidence from recent clinical trials in fibrotic interstitial lung diseases. Curr Opin Pulm Med. 2024 Sep 1;30(5):484-493.

7. Maher TM, et al. Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD). BMJ Open Respir Res. 2023 Sep;10(1):e001580. 

8. Phase 3 Trials of Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis (FIBRONEER-IPF) and Progressive Pulmonary Fibrosis (FIBRONEER-ILD). 2025 ATS.

9. Boehringer's nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study. Accessed January 2025. Available at: https://www.boehringer-ingelheim.com/us/topline-results-boehringers-phase-iii-ipf-study.

10. Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis. Accessed february 2025. Available at: https://www.boehringer-ingelheim.com/us/topline-results-boehringers-phase-iii-ild-study.